Abstract
BackgroundOutcomes for patients with refractory or relapsed soft-tissue (ST) sarcomas are poor. Immunotherapy with chimeric antigen receptor (CAR)-expressing lymphocytes has shown promise in pre-clinical models. However, efficacy has been limited...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
